Why lung cancer doesn't respond well to immunotherapy

by Anne Trafton,Massachusetts Institute of TechnologyA new MIT study explains why dendritic cells (green) in lymph nodes that drain from the lungs fail to stimulate killer T cells (white) to att

Updated on: January 08,2024

Why lung cancer doesn't respond well to immunotherapy

by Anne Trafton,Massachusetts Institute of TechnologyA new MIT study explains why dendritic cells (green) in lymph nodes that drain from the lungs fail to stimulate killer T cells (white) to att

Updated on:January 08,2024

“The power of science”: HPV vaccine proven to dramatically reduce cervical cancer

byLilly Matson| Analysis3 November 2021Share this articleAlmost all cervical cancers are caused by the human papilloma virus (HPV), depicted above.After decades of research,the UK im

Updated on: December 19,2023

“The power of science”: HPV vaccine proven to dramatically reduce cervical cancer

byLilly Matson| Analysis3 November 2021Share this articleAlmost all cervical cancers are caused by the human papilloma virus (HPV), depicted above.After decades of research,the UK im

Updated on:December 19,2023

Lung cancer screening guidelines perpetuate racial disparities, study finds

Lung cancer screening guidelines perpetuate racial disparities, study findsby Krista Conger,Stanford UniversityRacial Disparities in the Eligibility-Incidence (E-I) Ratio Through the US Preventi

Updated on: October 30,2023

Lung cancer screening guidelines perpetuate racial disparities, study finds

Lung cancer screening guidelines perpetuate racial disparities, study findsby Krista Conger,Stanford UniversityRacial Disparities in the Eligibility-Incidence (E-I) Ratio Through the US Preventi

Updated on:October 30,2023

Novel cell 'switches' found to promote lung cancer growth, treatment resistance

by Melissa Rohman,Northwestern UniversitySCLC cell lines have divergent gene regulatory networks and phenotypes. (A) Hierarchical clustering was performed using 53 SCLC cell lines. Silhouette wi

Updated on: December 21,2023

Novel cell 'switches' found to promote lung cancer growth, treatment resistance

by Melissa Rohman,Northwestern UniversitySCLC cell lines have divergent gene regulatory networks and phenotypes. (A) Hierarchical clustering was performed using 53 SCLC cell lines. Silhouette wi

Updated on:December 21,2023

Researchers identify new therapeutic target for colorectal cancer

byRockefeller University PressCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0Researchers at the University of Toronto have identified a key protein that support

Updated on: December 20,2023

Researchers identify new therapeutic target for colorectal cancer

byRockefeller University PressCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0Researchers at the University of Toronto have identified a key protein that support

Updated on:December 20,2023

Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

September 25, 2015Jason M. BroderickNivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.Padmanee Sharm

Updated on: October 24,2023

Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

September 25, 2015Jason M. BroderickNivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.Padmanee Sharm

Updated on:October 24,2023

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

by Impact Journals LLCEvaluation of the toxicity of MK256 in vivo. Credit:Oncotarget(2022). DOI: 10.18632/oncotarget.28305A new research paper titled "MK256 is a novel CDK8 inhibitor

Updated on: December 17,2023

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

by Impact Journals LLCEvaluation of the toxicity of MK256 in vivo. Credit:Oncotarget(2022). DOI: 10.18632/oncotarget.28305A new research paper titled "MK256 is a novel CDK8 inhibitor

Updated on:December 17,2023

New antibody shows strong potential as treatment against pancreatic cancer

New antibody shows strong potential as treatment against pancreatic cancerbyTranslational Genomics Research InstituteSIWA318H treatment depletes p16INK4apositive cells and reduces αSMA exp

Updated on: October 30,2023

New antibody shows strong potential as treatment against pancreatic cancer

New antibody shows strong potential as treatment against pancreatic cancerbyTranslational Genomics Research InstituteSIWA318H treatment depletes p16INK4apositive cells and reduces αSMA exp

Updated on:October 30,2023

Research reveals how synthesized plankton molecules inhibit cancer proteins

by Justin Jackson , Medical Xpressa, Chemical structure of reported PA and PB (in beige), and the revised structure of PB (in blue) in this work. b, A retrosynthesis targeting a minimally oxidized int

Updated on: October 14,2023

Research reveals how synthesized plankton molecules inhibit cancer proteins

by Justin Jackson , Medical Xpressa, Chemical structure of reported PA and PB (in beige), and the revised structure of PB (in blue) in this work. b, A retrosynthesis targeting a minimally oxidized int

Updated on:October 14,2023

Predicting lymphoma patients' treatment outcomes

byCedars-Sinai Medical CenterDistinct spatially resolved TME features according to relapse status. (A) Proportion for the indicated immune cell population by IMC-based cluster assignment. (B) Th

Updated on: December 26,2023

Predicting lymphoma patients' treatment outcomes

byCedars-Sinai Medical CenterDistinct spatially resolved TME features according to relapse status. (A) Proportion for the indicated immune cell population by IMC-based cluster assignment. (B) Th

Updated on:December 26,2023

Deep Learning in Cancer: Redefining Diagnosis, Prognosis, and Precision Oncology

Updated on: May 28,2025

Deep Learning in Cancer: Redefining Diagnosis, Prognosis, and Precision Oncology

Updated on:May 28,2025

Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

September 10, 2023Kristi RosaTreatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TK

Updated on: October 11,2023

Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

September 10, 2023Kristi RosaTreatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TK

Updated on:October 11,2023